Baird Initiates Coverage on Regeneron (REGN) with a Neutral
More News related to REGN
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Regeneron Announces Conference Call to Discuss Expanded Antibody Collaboration with Sanofi-aventis
- Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
- Regeneron Reports Third Quarter 2009 Financial and Operating Results
- RBC Downgrades Regeneron Pharmaceuticals (REGN) to Sector Perform
More News related to New Coverage
- Sidoti & Co Initiates Coverage on Stratasys (SSYS) with a Neutral
- ThinkEquity Initiates Coverage on Sourcefire (FIRE) with a Buy
- Raymond James Initiates Coverage on Knight Capital (NITE) with a Market Perform
- Raymond James Initiates Coverage on International Game Technology (IGT) with a Market Perform
- Thomas Weisel Initiates Coverage on UQM Technologies (UQM) with an Overweight
Baird initiates coverage on Regeneron (Nasdaq: REGN) with a Neutral rating.
Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Related Categories
New CoverageStocks Mentioned
+0.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
